These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

82 related articles for article (PubMed ID: 2115226)

  • 1. Repeated administration of (-)deprenyl leaves the mesolimbic dopaminergic activity unchanged.
    Gyarmati S; Hársing LG; Tekes K; Knoll J
    Acta Physiol Hung; 1990; 75 Suppl():133-4. PubMed ID: 2115226
    [No Abstract]   [Full Text] [Related]  

  • 2. Comparison of the effects of (-)deprenyl, 1-phenyl-2-propyl-aminopentane (MK-306) and amphetamine on the striatal and limbic dopaminergic system.
    Timár J; Yasar S; Knoll B; Knoll J
    Acta Physiol Hung; 1990; 75 Suppl():279-80. PubMed ID: 2115233
    [No Abstract]   [Full Text] [Related]  

  • 3. Long-term administration of (-)deprenyl (selegiline), a compound which facilitates dopaminergic tone in the brain, leaves the sensitivity of dopamine receptors to apomorphine unchanged.
    Timar J; Knoll B; Knoll J
    Arch Int Pharmacodyn Ther; 1986 Dec; 284(2):255-66. PubMed ID: 3103558
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Further proof that (-)deprenyl fails to facilitate mesolimbic dopaminergic activity.
    Timár J; Gyarmati Z; Tekes K; Härsing GL; Knoll J
    Pharmacol Biochem Behav; 1993 Nov; 46(3):709-14. PubMed ID: 8278449
    [TBL] [Abstract][Full Text] [Related]  

  • 5. R-(-)-deprenyl (Selegiline, Movergan) facilitates the activity of the nigrostriatal dopaminergic neuron.
    Knoll J
    J Neural Transm Suppl; 1987; 25():45-66. PubMed ID: 2828537
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The action of (-) deprenyl on monoamine turnover rate in rat brain.
    Zsilla G; Knoll J
    Adv Biochem Psychopharmacol; 1982; 31():211-7. PubMed ID: 6805258
    [No Abstract]   [Full Text] [Related]  

  • 7. Preferential effect of noncataleptogenic neuroleptics on mesolimbic dopaminergic function.
    Bartholini G
    Adv Biochem Psychopharmacol; 1977; 16():607-11. PubMed ID: 18902
    [No Abstract]   [Full Text] [Related]  

  • 8. The effect of (-) deprenyl (selegiline) on different behavioral changes induced by dopamine agonists in the rat.
    Timar J; Knoll B; Knoll J
    Pol J Pharmacol Pharm; 1988; 40(6):659-66. PubMed ID: 2908366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect of repeated doses of (-) deprenyl on the dynamics of monoaminergic transmission. Comparison with clorgyline.
    Zsilla G; Földi P; Held G; Székely AM; Knoll J
    Pol J Pharmacol Pharm; 1986; 38(1):57-67. PubMed ID: 3020531
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic L-deprenyl-induced up-regulation of the dopamine uptake carrier.
    Wiener HL; Hashim A; Lajtha A; Sershen H
    Eur J Pharmacol; 1989 Apr; 163(1):191-4. PubMed ID: 2501102
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Irregular chronic stress related selective presynaptic adaptation of dopaminergic system in rat striatum: effects of (-)deprenyl and amitriptyline.
    Tekes K; Tothfalusi T; Magyar K
    Acta Physiol Pharmacol Bulg; 1986; 12(4):21-8. PubMed ID: 3107343
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic L-deprenyl does not alter the restoration of striatal dopamine in MPTP-lesioned mice.
    Wiener HL; Hashim A; Lajtha A; Sershen H
    J Neurosci Res; 1989 Jul; 23(3):326-9. PubMed ID: 2504936
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A (-) deprenyl-derived new spectrum psychostimulant.
    Knoll B; Yasar S; Timár J; Knoll J
    Acta Physiol Hung; 1990; 75 Suppl():173-4. PubMed ID: 1973564
    [No Abstract]   [Full Text] [Related]  

  • 14. The effect of repeated treatment with brofaromine, moclobemide and deprenyl on alpha 1-adrenergic and dopaminergic receptors in the rat brain.
    Klimek V; Nowak G; Zak J; Maj J
    Neurosci Lett; 1990 Jan; 108(1-2):189-94. PubMed ID: 2154722
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lasting changes in high affinity 3H-spiperone binding to the rat striatum and mesolimbic area after chronic methamphetamine administration: evaluation of dopaminergic and serotonergic receptor components.
    Akiyama K; Sato M; Kashihara K; Otsuki S
    Biol Psychiatry; 1982 Dec; 17(12):1389-402. PubMed ID: 7159638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Deprenyl suppresses the oxidant stress associated with increased dopamine turnover.
    Cohen G; Spina MB
    Ann Neurol; 1989 Nov; 26(5):689-90. PubMed ID: 2510589
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [The role of the central dopaminergic system in the mechanisms of action of antidepressive drugs and electroconvulsive therapy].
    Vetulani J
    Psychiatr Pol; 1988; 22(2):89-98. PubMed ID: 3222391
    [No Abstract]   [Full Text] [Related]  

  • 18. [Medicamentous strategy for improving the quality of life in the senescence].
    Knoll J
    Wien Med Wochenschr Suppl; 1986; 98():1-18. PubMed ID: 3097965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The mesolimbic dopamine system: the final common pathway for the reinforcing effect of drugs of abuse?
    Pierce RC; Kumaresan V
    Neurosci Biobehav Rev; 2006; 30(2):215-38. PubMed ID: 16099045
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Possible mechanism of action of deprenyl in parkinsonism.
    Paterson IA; Juorio AV; Boulton AA
    Lancet; 1990 Jul; 336(8708):183. PubMed ID: 1973501
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.